SafeRx Pharmaceuticals

Our patented ARO drug platform solves a critical dimension of the opioid crisis and will gain exclusive access to a >$12B addressable U.S. market in 2 ½ years.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Lenox, MA, USA
  • Currency USD
  • Founded June 2020
  • Employees 3
  • Incorporation Type C-corp
  • Website saferxpharmaceuticals.com

Company Summary

SafeRx is developing our patented platform of Alcohol-Resistant Opioids, which solve a critical, previously unaddressed dimension of the opioid crisis responsible for nearly ¼ of fatal overdoses. FDA approval of our two inaugural Alcohol-Resistant Opioids is expected in less than 3 years and on a total budget of less than $15 million. Once approved, these products will gain exclusive access to a greater than $12 billion addressable U.S. market.

Team

  • Michael Presti, MD PhD
    Chief Executive Officer

    - MD and PhD (Neuroscience); University of Florida
    - NIH National Research Service Awardee
    - Master’s in Business Management; Warrington School, University of Florida
    - Neurology residency and fellowship training at Mayo Clinic Rochester
    - Diplomat of the ABPN and ABSM
    - Inventor with multiple utility patents issued from USPTO

  • Raymundo Sison
    Chief Product Officer

    - 25+ yrs in pharmaceutical formulation dev, product launch and commercialization
    - Created licensing, acquisition & commercialization opportunities for OptiNose, Lonza Group, Teva Pharma
    - Expert in outsourced pharma development and virtual supply chain coordination
    - Involved in product launches of Roxybond and Morphabond, both abuse-deterrent formulation-labeled opioids

  • Joe Suarez
    Chief Financial Officer

    - 30+ years of progressive financial experience across life science companies
    - Expertise in strategic planning, mergers, acquisitions, private placements, financial reporting, accounting, budgeting, and financial planning and analysis
    - Additional experience in operations, commercialization, and product reimbursement
    - Former Chief Business Officer of Arisaph Pharmaceuticals

Advisors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free